When Are Your Startup Options Worth It?

Run your numbers first

Put in your own cap table, strike price, and exit scenario. The rest of this post explains every input and what drives each output.

The 409A and how join timing determines your upside

Options are typically granted at fair market value (FMV) of the common stock on the date of grant, based on a 409A valuation. The key insight: FMV of common stock is not the same as the preferred stock price investors pay. Common stock sits below the liquidation preference in the capital structure, so it is usually worth less.

What this means in practice: as a company raises successive rounds at higher preferred prices, the 409A usually rises too, but it may rise more slowly because common-stock value reflects both the company's progress and the growing preference stack sitting above it. Early hires get strike prices when the 409A is low. Later hires get strike prices when it is much higher.

Generate Biomedicines IPO case: share-price math

Generate Biomedicines (Nasdaq: GENB) IPO'd in February 2026. That means the actual Generate exit is best treated as IPO share-price math: preferred stock converted to common, and option value was driven by the public share price minus each employee's strike price. The S-1 is still useful because it discloses the 409A valuations the board used to set employee strike prices.

The discount from preferred price exists because 409A valuations commonly use option-pricing, probability-weighted, or hybrid methods that account for the preference stack and the probability distribution of exit outcomes. It is not an arbitrary haircut. As the company approaches IPO, the discount often closes because in an IPO preferred stock typically converts to common and the preference stack disappears.

How cohort timing translates into actual dollars

Using Generate's actual IPO price of $16.00, option spread at IPO is simply max($16.00 - strike price, $0). For an employee granted options at each stage:

The early Series A-era strike is roughly 50x lower than the pre-IPO strike. That gap is the main driver of early-employee advantage. It reflects the genuine risk taken at a time when the company had less validation, less capital, and more uncertainty.

That is the real Generate case: an IPO exit where the relevant output is share price. The acquisition math below is a separate hypothetical used to show why the same pre-IPO cap table would behave differently if a company sold before or instead of going public.

The preferred stack: what it means in an acquisition

At IPO, preferred stock converts to common at 1:1. Liquidation preferences do not apply. Every share participates at the same price.

In an acquisition, it works differently. Preferred shareholders usually receive the greater of their liquidation preference or the value they would receive by converting to common. The liquidation preference is typically the original issue price plus any accrued dividends. If preferred takes the preference, remaining value flows to common and optionholders; if preferred converts, everyone shares pro-rata as common.

Generate pre-IPO cap table (hypothetical M&A stress test)

Generate did not exit through M&A; it went public. But if the same disclosed pre-IPO cap table were used as a hypothetical acquisition stress test, preferred would receive the greater of the $960.5M preference stack or the value it would receive by converting to common. If preferred took the preference at a $1.5B sale, the remaining $539.5M would be distributed across common and option shares, not across the preferred shares that already took their preference. That yields roughly $6.63/share for common and optionholders.

The preferred conversion point is around a $1.70B sale. At that point, the preference path and conversion path both imply roughly $9.12/share. Above that, preferred converts because its pro-rata as-converted value is worth more than the liquidation preference. Conversion does not make common go to zero; it changes the denominator. Everyone shares the exit value across 105.3M preferred shares plus 81.3M common/options, so common-share price keeps increasing with exit value, but more slowly than it would if preferred stayed out of the denominator.

Treat this as a hypothetical worked reading of the S-1, not a claim about Generate's actual outcome and not a legal conclusion about what every holder would receive. The filing discloses the relevant share counts, issue prices, cumulative dividends, option overhang, and liquidation language, but actual proceeds in a real M&A transaction would depend on final deal terms and the company's option-plan mechanics.

This is why exit valuation matters so much, and why the preference stack is the critical number to understand. It is not the company valuation from the press release. It is the threshold below which common stock may receive little or nothing in a preference-path acquisition.

Hypothetical M&A: at what exit would common equity win?

This is not Generate's actual exit. It is a sensitivity table using GENB's disclosed pre-IPO cap table: $960.5M total liquidation preference, 105.3M preferred shares, 50.3M common shares, and 31.0M outstanding options. The table below models a simplified version of the S-1 liquidation rule: preferred receives the greater of its preference or as-converted value. "Strike below this is in the money" means the modeled common-share price at that exit; if your strike is lower than that number, your option has gross spread value.

An employee with GENB's $3.88 average option strike needs the modeled common-share price to exceed $3.88 before those options have spread value. In this simplified M&A stress test, that share-price threshold is reached at roughly a $1.28B acquisition value. A Series B-era hire with a ~$2.50 strike needs the modeled common-share price to clear $2.50, which happens around $1.16B. Above the preferred-conversion point, the option threshold continues to rise with total exit value, but each additional dollar is shared across the full as-converted capitalization rather than only common and options.

These thresholds are directional. They assume the S-1 share counts and liquidation preference are interpreted correctly, all modeled options remain in the denominator, transaction expenses are ignored, and the preferred behaves according to the simplified greater-of-preference-or-conversion rule.

Why headline exits can mislead

A press-release valuation is not the same thing as the price paid to common shareholders. Before you estimate your option value, identify the structure of the transaction.

Repricings and recapitalizations can also reset the employee math. A company can lower option strike prices after a valuation correction, cancel and reissue grants, or restructure the capitalization. That may help employees, but it means the original offer letter alone is not enough to model the outcome.

ISOs, AMT, and the departure clock

Alternative Minimum Tax on ISO exercise

When you exercise an ISO, the spread between your strike price and the FMV on the exercise date is an AMT preference item. It can increase alternative minimum taxable income even if you have not sold a share and received no cash. AMT is not simply "28% of the spread"; the actual bill depends on your income, exemption, regular tax, credits, and state taxes. But a large ISO spread can create a real cash tax problem.

AMT credits can carry forward and may offset regular tax in future years, but that does not solve the timing problem. Employees who cannot fund the tax may need liquidity sooner than planned, and selling early can turn a planned ISO qualifying disposition into a disqualifying disposition.

NSOs do not have the same AMT preference-item issue. The spread at exercise is ordinary income in the year of exercise. The tradeoff is that NSO spread income is taxed at ordinary-income rates, while ISO gains from a qualifying disposition (held at least 1 year after exercise and 2 years from grant) can receive long-term capital gains treatment for federal tax purposes.

The 90-day departure clock

To preserve ISO tax treatment after leaving a company, vested ISOs generally must be exercised within three months after employment ends. Many option plans also terminate vested options after that window. Some plans allow a longer post-termination exercise period, but exercises after the ISO window are usually treated as NSOs.

The pressure this creates: you must decide whether to exercise -- paying the strike price in cash and potentially triggering AMT -- with no guarantee of when or at what price the company will exit. If the company never exits above your strike, you lose the exercise cash. If the company exits well, having exercised early lets you start the LTCG holding clock.

Some companies extend the post-termination exercise window to 5 or 10 years. It is a meaningful employee-friendly term worth negotiating. A longer window may sacrifice ISO treatment after three months, but it can reduce the binary risk of exercising into uncertainty.

Terms worth understanding before you sign

Startup options vs. pharma RSUs: the mechanics side by side

RSUs at a public pharma company are grants of actual shares that vest on a schedule. No exercise cost, no AMT, and you receive shares (or cash equivalent) at vest regardless of any acquisition or IPO. The tradeoff is that upside is bounded by stock performance -- a 20x return requires the company's stock to go up 20x, which for large-cap pharma is not realistic.

The RSU comparison also needs to include stock price appreciation. A $30K/year RSU grant at a company whose stock grows 7%/year is worth more than $30K by the time it vests.

The calculator above lets you model both. The relevant comparison is not the headline grant size but the probability-weighted after-tax value. A startup option grant with a large preference stack ahead of it has a different expected value than the nominal dollar amount suggests.

Summary

Options can deliver significant financial returns, particularly for early employees at companies that reach high valuations through clean exits -- IPOs or acquisitions well above the preference stack. The key variables are: your strike price relative to exit price, the total liquidation preference ahead of you, the exit structure, and the tax path you take.

As a founder, the questions I encourage every employee to ask before signing an offer:

1. What is the current total liquidation preference across all preferred series, including accrued dividends?
2. Are Series B and C dividends cumulative? At what rate?
3. Is the preferred participating or non-participating?
4. What is the post-departure exercise window? What happens to ISO treatment after three months?
5. Has there been a recap? If so, how were employee options treated?
6. What exit valuation would clear the preference stack and put your strike in the money?
7. If you exercise ISOs on departure, what is the AMT exposure on the spread?

The calculator at the top of this post lets you work through any scenario with your own numbers. The math is not complicated once you know the inputs -- and those inputs are knowable, if you ask for them.

Citing This Work

If you found this resource helpful or reference this options payoff framework in your work, please cite:

@misc{ubi2026startupoptionsworthit,
  author = {UniBio Intelligence},
  title = {Are Your Startup Options In the Money?},
  year = {2026},
  url = {https://unibiointelligence.com/blog/startup-options-worth-it},
  note = {Accessed: 2026-06-20}
}